SEC Secures 6.25 Billion Won in Government Funding...Participates in National Strategic Project for 'FLASH Radiotherapy 1-Second Cancer Treatment Device' View original image

SEC, a company specializing in electron beam core technology, will participate in the government-led national strategic project to develop next-generation FLASH radiotherapy devices and is set to expand its business in medical linear accelerators (LINAC).


On July 6, SEC announced through a disclosure that it will participate as a joint research institution in the "FLASH Radiotherapy 1-Second Cancer Treatment Device Strategic Research Project" promoted by the National Research Council of Science & Technology (NST) under the Ministry of Science and ICT.


This project will run for approximately 57 months, from April 2026 to December 2030, with a total budget of about 27.09 billion won. Of this, the government will provide 25 billion won in support. SEC will receive 6.25 billion won in government-funded research grants and will be responsible for developing the core components of the FLASH radiotherapy device. This amount is equivalent to about 17.7% of the company’s equity capital as of the end of last year.


The strategic research project is led by the Korea Research Institute of Standards and Science (KRISS), with Seoul National University Hospital, Dongnam Institute of Radiological & Medical Sciences, Korea Institute of Radiological & Medical Sciences, and Electronics and Telecommunications Research Institute (ETRI) participating as joint research institutions. Yonsei University and Oncosoft are working together as subcontracted institutions.


FLASH radiotherapy is a next-generation technology that delivers ultra-high-dose electron beams in less than one second. It is regarded as a groundbreaking technology that can significantly shorten treatment times compared to conventional radiotherapy. Although global medical device companies and research institutions are pursuing commercialization, actual commercial cases remain limited.


The core goal of this research project is to develop a treatment system based on a medical linear accelerator, the key equipment for FLASH radiotherapy. Participating institutions will jointly develop ultra-high-dose electron beam generation technology, dose control technology, treatment systems, and clinical application-based technologies.


SEC expects that this project will serve as an opportunity to expand its industrial linear accelerator technology into the medical field. The company has already broadened its business areas from industrial X-ray and linear accelerator technology to high-bandwidth memory (HBM), semiconductors, defense, and medical fields. Through this national strategic project, SEC plans to accelerate the acquisition of core technologies for medical linear accelerators and foster new growth engines.


An SEC representative stated, "Our participation in this strategic research project will mark an important turning point as we expand our linear accelerator technology into the medical field," adding, "Through this national strategic project involving both government-funded research institutes and medical institutions, we will do our utmost to secure core technologies for next-generation FLASH radiotherapy devices."



This participation in the national strategic project is expected to serve as an opportunity for SEC to expand its industrial linear accelerator technology into the medical field and to secure core technologies for next-generation radiotherapy devices.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing